Pacira BioSciences Inc. (PCRX)

NASDAQ: PCRX · Real-Time Price · USD

26.87

-0.03 (-0.11%)

At close: May 01, 2025, 3:32 PM

-0.11% (1D)

Bid	26.85
Market Cap	1.24B
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
EPS (ttm)	-2.15
PE Ratio (ttm)	-12.5
Forward PE	7.23
Analyst	Buy

Ask	26.89
Volume	287,308
Avg. Volume (20D)	903,906
Open	26.66
Previous Close	26.90
Day's Range	26.35 - 27.08
52-Week Range	11.16 - 31.67
Beta	0.71

About PCRX

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted ner...

Sector Healthcare

IPO Date Feb 3, 2011

Employees 788

Stock Exchange NASDAQ

Ticker Symbol PCRX

Website https://www.pacira.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $25, which is a decrease of -6.96% from the latest price.

Stock Forecasts

Next Earnings Release

Pacira BioSciences Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+14.67%

Pacira BioSciences shares are trading higher after... Unlock content with Pro Subscription

3 weeks ago

-0.82%

Pacira BioSciences shares are trading higher after the company announced settlement of litigation related to EXPAREL patents.

News

1 week ago · zacks.com

Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago · accessnewswire.com

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Compan...

3 weeks ago · seekingalpha.com

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which...

3 weeks ago · zacks.com

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

3 weeks ago · zacks.com

PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study

Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.

1 month ago · zacks.com

Pacira Surges 66.8% in Six Months: How Should You Play the Stock?

PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern.

1 month ago · seekingalpha.com

Pacira BioSciences: Back On An Uptrend After Positive Developments

Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic,...

1 month ago · accessnewswire.com

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securi...